Cardiol Therapeutics Secures $11M Funding to Advance Heart Disease Pipeline Following Breakthrough ARCHER Trial Results
- Cardiol Therapeutics completed an $11 million private placement offering that extends the company's cash runway into Q3 2027 and fully funds the Phase III MAVERIC trial through FDA submission.
- The ARCHER trial demonstrated significant reduction in left ventricular mass in myocarditis patients, marking the first evidence of structural and remodeling improvement in this condition.
- The funding will accelerate development of next-generation therapy CRD-38 for heart failure, with partnership discussions advancing with leading pharmaceutical companies.
- CardiolRx has received FDA Orphan Drug Designation for pericarditis treatment, with the company pursuing additional designation for myocarditis based on ARCHER findings.
Cardiol Therapeutics Inc.
Posted 4/7/2025
Cardiol Therapeutics Inc.
Posted 6/22/2022
Cardiol Therapeutics Inc.
Posted 11/30/2022